Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Q4 Revenue Fell 12.7 Percent, Expects Q1 05 Receipts to Slide 32-40 Percent

NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen today reported a fall-off in total revenue in the fourth quarter, decreased R&D spending, and net income resulting from its sale late last year of its BioSepra business.

 

Total revenues for the three months ended Dec. 31., 2004, fell 12.7 percent to $10.1 million from $11.6 million year over year.

 

Ciphergen said R&D spending in the fourth quarter shrank 35.6 percent to $3.7 million from $5.8 million year over year.

 

The company said net income in the quarter swelled to $10.3 million, or $.35 per basic share, from a net loss of $6.7 million, or $.23 per basic share. The turnaround was the result of Ciphergen's sale late last year of its BioSepra unit for $35.8 million.

 

Ciphergen said it had around $35.4 million in cash and equivalents and $2.2 million in short-term investment as of Dec, 31, 2004.

 

Looking ahead, Ciphergen said it expects first-quarter revenue to fall between 32 and 40 percent to between $8 million and $9 million from $13.3 million in the first quarter of 2004.

 

However, the company expects 2005 revenue to increase by as much as 20 percent to between $44 million from $48 million from $40.2 million in 2004.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.